HealthcareServices

Ribose-Nucleic Acid (RNA)-Based Therapeutics Market 2026–2030: Emerging Trends and Forecast Opportunities

March 2, 2026March 3, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the ribose-nucleic acid (rna)-based therapeutics market from 2026–2035 with trusted insights from The Business Research Company

How is the Ribose-Nucleic Acid (RNA)-Based Therapeutics Market size predicted to change over the forecast window of 2026–2035?

The market for ribose-nucleic acid (rna)-based therapeutics has experienced robust expansion in recent times. This market is projected to expand from $17.22 billion in 2025 to $18.75 billion by 2026, exhibiting a compound annual growth rate (CAGR) of 8.9%. Historically, this expansion has been driven by factors such as progress in molecular biology research, the early achievements of rna-based drugs, the broadening scope of genetic disease investigations, a rise in pharmaceutical R&D spending, and an enhanced comprehension of gene regulation.

The ribose-nucleic acid (rna)-based therapeutics market size is anticipated to experience substantial growth in the coming years. It is projected to expand to $26.17 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.7%. This expansion during the forecast period is fueled by factors such as a rise in regulatory approvals for rna therapies, escalating demand for personalized medicine, the broadening of oncology-focused rna pipelines, increased investments in delivery technologies, and more frequent collaborations between biotech firms. Key trends anticipated in the forecast period encompass the increasing development of rna-based targeted therapies, a greater adoption of sirna and aso technologies, an intensified focus on rare and genetic disorders, the expansion of clinical trials for rna therapeutics, and innovations enhancing drug delivery systems.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=18454&type=smp

Which Drivers Are Contributing To The Expansion Of The Ribose-Nucleic Acid (RNA)-Based Therapeutics Market?

The ribose-nucleic acid (RNA)-based therapeutics market is anticipated to expand in the future, driven by the rising incidence of cancer. Cancer is defined as a disease characterized by the uncontrolled proliferation and dissemination of aberrant cells, which can prove fatal if left untreated. The higher occurrence of cancer can be attributed to factors such as an aging demographic, shifts in lifestyle, increased exposure to various risks, and enhanced diagnostic techniques. RNA-based therapeutics present a promising approach to cancer treatment, as they directly target the genetic and molecular pathways involved in the disease. For example, data from August 2023 provided by the Australian Institute of Health and Welfare, an Australia-based government health body, indicated that approximately 151,000 individuals were diagnosed with cancer (excluding basal cell carcinomas (BCC) and squamous cell carcinomas (SCC) of the skin) in 2021, with projections showing this number will rise to 185,000 by 2030. Consequently, the growing incidence of cancer is a key factor propelling the ribose-nucleic acid (RNA)-based therapeutics market.

What Segment Categories Are Covered In The Ribose-Nucleic Acid (RNA)-Based Therapeutics Market?

The ribose-nucleic acid (rna)-based therapeutics market covered in this report is segmented –

1) By Type: RNA Interference (RNAi), RNA Antisense

2) By Technology: Enabling Technology, Enabled Technology

3) By Therapeutic Area: Oncology, Genetic Disorder, Ophthalmology, Hematological Disorders, Acute Hepatic Porphyria (AHP), Other Therapeutic Areas

4) By End User: Research Institutes, Hospitals And Clinics

Subsegments:

1) By RNA Interference (RNAi): Small Interfering RNA (siRNA), MicroRNA (miRNA)

2) By RNA Antisense: Antisense Oligonucleotides (ASOs), Antisense RNA

What Long-Term Trends Are Expected To Shape The Future Of The Ribose-Nucleic Acid (RNA)-Based Therapeutics Market?

Companies operating in the ribose nucleic acid (RNA)-based therapeutics market are primarily focused on developing innovative medical solutions, such as messenger RNA (mRNA)-based booster vaccines. These efforts aim to improve the effectiveness of immunization, address newly emerging viral variants, and increase the overall durability of immunity provided by vaccines. An mRNA-based booster vaccine functions by using messenger RNA to instruct cells to generate a protein, which then enhances the body’s immune response against a specific pathogen. For example, in June 2023, Gennova Biopharmaceuticals Ltd., an India-based pharmaceutical company, introduced GEMCOVAC-OM, recognized as India’s first mRNA booster vaccine specifically targeting the Omicron variant of COVID-19. This booster is considered vital due to the original vaccines’ limited efficacy against the Omicron variant. By utilizing mRNA technology, GEMCOVAC-OM works to boost immunity and deliver enhanced protection against the evolving virus.

Which Leading Companies Dominate The Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Share?

Major companies operating in the ribose-nucleic acid (rna)-based therapeutics market are F Hoffmann La Roche AG, Eli Lilly And Company, Novo Nordisk AS, Regeneron Pharmaceuticals, Biogen Inc., BioNTech, Alnylam Pharmaceuticals, Sarepta Therapeutics, Ionis Pharmaceuticals, Akcea Therapeutics Inc, Arrowhead Pharmaceuticals, Dicerna Pharmaceuticals, Wave Life Sciences, Quark Pharmaceuticals, Tekmira Pharmaceuticals, ReCode Therapeutics, Arbutus Biopharma Corporation, Benitec Biopharma Inc., Olix Pharmaceuticals, Alltrna Inc., Orbital Therapeutics, Moderna Inc., CureVac NV, Silence Therapeutics plc, ProQR Therapeutics NV

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/ribose-nucleic-acid-rna-based-therapeutics-global-market-report

How Does The Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Perform Across Major Global Regions?

North America was the largest region in the ribose-nucleic acid (RNA)-based therapeutics market in 2025. The regions covered in the ribose-nucleic acid (rna)-based therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=18454&type=smp

Browse Through More Reports Similar to the Global Ribose-Nucleic Acid (RNA)-Based Therapeutics Market 2026, By The Business Research Company

Rna Targeting Small Molecules Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecules-therapeutics-global-market-report

Mrna Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/mrna-therapeutics-global-market-report

Nucleic Acid Based Gene Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/nucleic-acid-based-gene-therapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795